Gyre Therapeutics Files 8-K on Financials
Ticker: GYRE · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
Gyre Therapeutics dropped an 8-K detailing financials - former Catalyst Biosciences/Targacept.
AI Summary
On March 26, 2024, Gyre Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
Why It Matters
This 8-K filing provides an update on Gyre Therapeutics' financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- GYRE THERAPEUTICS, INC. (company) — Registrant
- CATALYST BIOSCIENCES, INC. (company) — Former Company Name
- TARGACEPT INC (company) — Former Company Name
- 20240326 (date) — Report Date
- 20240325 (date) — Date of Earliest Event Reported
- 12770 High Bluff Drive, Suite 150 San Diego, CA 92130 (address) — Principal Executive Offices
- (619) 949-3681 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Gyre Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 25, 2024.
What are the former names of Gyre Therapeutics, Inc. mentioned in the filing?
The filing mentions that Gyre Therapeutics, Inc. was formerly known as CATALYST BIOSCIENCES, INC. and TARGACEPT INC.
What is the business address of Gyre Therapeutics, Inc.?
The business address of Gyre Therapeutics, Inc. is 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
What is the telephone number for Gyre Therapeutics, Inc.?
The telephone number for Gyre Therapeutics, Inc. is (619) 949-3681.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-03-25 21:55:13
Filing Documents
- gyre-20240326.htm (8-K) — 44KB
- gyre-ex99_1.htm (EX-99.1) — 262KB
- img51893664_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-036135.txt ( ) — 452KB
- gyre-20240326.xsd (EX-101.SCH) — 25KB
- gyre-20240326_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 26, 2024, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated herein shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated March 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: March 26, 2024 By: /s/ Han Ying, Ph.D. Name: Han Ying, Ph.D. Title: Chief Executive Officer